Skip to main content

Table 5 Other dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

From: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Patient no. Age (yr) Sex Diagnosis Druga Active treatment Event Clinical description Localization Time to event Biopsy Comedicationb Permanent withdrawal anti-TNF-α Therapy Course
1 56 f RA A Yes Lymphomatoid papulosis-like eruption Macular erythematosquamous lesions Lower arms, upper legs and trunk 2.6 Yes naproxen No None Recovery
2 53 f RA A Yes Rosacea Diffuse erythema, scaling, telangiectasias Head and face 1.9 Yes prednisolone, captopril, indomethacin, midazolam No Topical Persisting
3 74 f RA E Yes Pruritus Itch Trunk 2.5 No None No Topical Unknown
4 61 f RA I No Ecchymoses Ecchymoses Hands and feet 25.9 No AZA, prednisolone No Topical Partial recovery
5 58 f RA I Yes Drug-induced systemic lupus emythematosus Discoid erythematous lesions, aphthous lesions, ANA positive, anti-ds-DNA positive Hands, face, scalp 20.0 No MTX Yes Topical and systemic Recovery, no rechallenge
6 68 m RA I Yes Transient swelling of unknown cause Transient swelling 2 × 3 cm Scalp 20.0 No MTX, folic acid, naproxen No None Recovery
7 52 f RA L Yes Dermatomyositis Livid erythema, raised CPK, decreased proximal muscular strength Inner upper arms and legs 2.5 Yes None Yes None Recovery
8 53 m RA L No Erythema nodosum Painful erythematous nodules Lower legs 7.4 Yes AZA, naproxen, paracetamol No Topical Partial recovery
  1. aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bMTX, methotrexate; AZA, azathioprine. CPK, creatinine phosphokinase; f, female, m, male.